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ABSTRACT: The first examples of Cu-catalyzed γ-selective allylic alkenylation using organozinc rea-
gents are reported. (E)-alkenylzinc iodides were prepared by Fe-catalyzed reductive coupling of termi-
nal arylalkynes with alkyl iodides. In the presence of a copper catalyst, these reagents reacted with al-
lylic bromides derived from Morita-Baylis-Hillman alcohols to give 1,4-dienes in high yields. The reac-
tions are highly γ-selective (generally γ/α > 49:1) and tolerate a wide range of functional groups such as 
ester, cyano, keto, and nitro. 
Metal-catalyzed allylic substitution using organozinc reagents is a versatile method for C-C bond for-
mation. Unlike alkylzinc1-3 and arylzinc4, 5 reagents (Scheme 1, a and b) which are widely used in these 
reactions, alkenylzinc reagents are rarely employed. There are only few examples of catalytic allylic 
alkenylation using alkenylzinc reagents to yield 1,4-dienes, which are ubiquitous in nature and represent 
an important class of synthetic building blocks .5-10 
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Scheme 1. Metal-catalyzed allylic substitution with organozinc reagents 
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Alkenylzinc compounds are commonly prepared11 by direct Zn insertion into the carbon-halogen bond 
of alkenyl halides,12, 13 or by transmetallation from alkenyl organometallic reagents.14 Both approaches 
are limited by the difficulty to obtain stereochemically pure alkenyl halides.15 Alkenylzinc reagents can 
also be prepared by carbozincation of alkynes with organozinc reagents.16 This approach is potentially 
stereoselective, but it requires reactive organometallic reagents which can be hard to handle or can low-
er functional group compatibility. We have recently reported Fe-catalyzed reductive coupling of aryla-
cetylenes with alkyl halides to form cis-alkenes. Mechanistic studies indicated that the reaction proceed-
ed via formation of (E)-alkenylzinc intermediates (eq 1).17,18 Thus, this reaction provides an easy access 
to stereochemically pure alkenylzinc reagents 1 without the need of sensitive organometallic reagents. 
Here we describe a Cu-based catalytic system for the reactions of these alkenylzinc reagents with allylic 
bromides (Scheme 1, c). To the best of our knowledge, this is the first γ-selective catalytic allylic 
alkenylation. The few precedents of catalytic allylic alkenylation either employed symmetrical allylic 
substrates12,19-21 or were α-selective.22,23 
Ar + R1-X
FeBr2
 
catalyst
Zn reductant
DMA, r.t. or 60°C
Ar R1
XZn
H2O Ar R1
R1
 = 1°, 2°, 3° alkyl
X = I, Br generally Z/E > 101
2
(1)
 
 
 
  
3 
Table 1. Optimization of reaction conditions of (E)-alkenylzinc iodides allylation 
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entry addition rate, mL/h catalyst (mol%) solvent (mL) time, h yieldb), % 
(4a:4ab) 
1c) 3.0  CuBr·SMe2 (10) DCM (2) 3.5 58 (71:1) 
2c) 3.0  (MeCN)4CuPF6 (10) DCM (2) 3.5 63 (66:1) 
3c) 3.0  (CuOTf)2·C6H6 (10) DCM (2) 3.5 53 (40:1) 
4c) 3.0  CuCl·2LiCl (10) DCM (2) 3.5 65 (45:1) 
5c) 3.0  CuCN·2LiCl (10) DCM (2) 3.5 74 (70:1) 
6c) 3.0 CuNHCd) (5) DCM (2) 3.5 <1 (n.d.) 
7c) 1.0  CuCN·2LiCl (5) DCM (2) 24 88 (56:1) 
8c) 1.0  CuCN·2LiCl (5) THF (2) 24 77 (42:1) 
9e) 1.0  CuCN·2LiCl (5) DCM (2) 24 93f) (68:1) 
10e) 1.0  - DCM (2) 24 1 (n.d.) 
a) Phenylacetylene (0.5 mmol, 1 equiv.), iodocyclohexane (1.5 equiv.), Zn (1.5 equiv.), TMSCl 
(20 mol%), FeBr2 (10 mol%) were stirred in DMA (1 mL) overnight (17-19 h). The resulting solution 
was used directly for the reactions with allylic bromides; b) Uncalibrated GC yield of the isomeric mix-
ture (4a + 4aa + 4ab), corrected by number of carbons; c) 0.35 mmol of 3a was used; d) Chloro[1,3-
bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) was used as catalyst; e) 0.25 mmol of 3a was 
used; f) 4a:4aa  12:1. 
Allylic halides derived from Morita-Baylis-Hillman (MBH) alcohols were chosen because the prod-
ucts contain both an activated C-C double bond and an electron-withdrawing group that are prone to 
further transformations. A diverse number of substrates are available thanks to the large scope of MBH 
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reaction.24 Moreover, earlier works25-27 showed that alkylation of MBH alcohols-derived allylic halides 
could be γ-selective. It was found that under Cu-catalysis ethyl (Z)-2-(bromomethyl)-3-phenylacrylate 
(3a) reacted with 1a, prepared by Fe-catalyzed reductive coupling of phenylacetylene and iodocyclo-
hexane, to give the corresponding γ-product 4a with high regioselectivity (Table 1). Among various 
copper catalysts, CuCN·2LiCl gave the highest yield and γ-selectivity (Table 1, entries 1-6). The yield 
could be improved using longer reaction time (24 h) and a slower addition rate with 5 mol% of 
CuCN·2LiCl as catalyst (Table 1, entry 7). Replacing dichloromethane (DCM) by tetrahydrofuran 
(THF) as the solvent led to a lower yield (Table 1, entry 8). The highest yield was obtained using 5 
mol% of CuCN·2LiCl in DCM at -30°C for 24 h with 0.25 mmol of 3a and 1a prepared on 0.5 mmol 
scale (Table 1, entry 9). Only a trace amount of product was obtained without a copper catalyst (Table 1, 
entry 10). 
Table 2 shows the scope of this reaction with respect to (E)-alkenylzinc reagents. Despite the presence 
of a complex mixture of metal ions and unreacted organic starting materials and side-products, the de-
sired dienes 4a-g were obtained in high isolated yields and with high Z/E selectivity. In all cases the 
products were almost exclusively γ-regioisomers (γ/α > 49:1).  Various substituents on the aryl rings of 
the (E)-alkenylzinc reagents were tolerated (1a-1d, 1g). The R1 group of the (E)-alkenylzinc reagents 
can be either cyclic (1a, 1f) or acyclic (1d, 1e). 
Table 2. Scope of (E)-alkenylzinc reagent 
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O
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a) Isolated yields of pure products (as a mixture of isomers); b) Determined by 1H NMR. Similar val-
ues were obtained by GC; c) exo/endo of the corresponding alkene is > 50:1.17 
The scope of 2-(bromomethyl)acrylates is shown in Table 3. Both aryl- (3a-e) and heteroarylsubstitut-
ed (3f) substrates could be used. The reactions were again highly γ-selective (γ/α > 49:1) and Z-
selective. Electron-withdrawing substituents in the aryl ring generally led to high yields, except for 4k, 
which has a nitro group in ortho-position of the phenyl ring. The steric influence of this nitro group 
probably led to the modest yield (49%). An electron-rich 2-furylsubstituted substrate also reacted in a 
high yield (3f). A crystal structure of compound 4k was determined (Figure 1) to confirm the regioselec-
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tivity and diastereoselectivity of the reaction. 
 
Table 3. Scope of aryl- and heteroarylsubstituted 2-(bromomethyl)acrylates 
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a) Isolated yield of pure product (as a mixture of isomers). b) Determined by 1H NMR (similar values 
were obtained by GC). 
 
Figure 1. X-Ray structure of compound 4k. Thermal ellipsoids are drawn at 50% probability level. Hy-
drogen atoms are omitted. Color code: red for O; blue for N; grey for C. 
Previously allylic substitution with MBH alcohols-derived allylic bromides was limited to reactions of 
3-aryl-2-(bromomethyl)acrylates.25 In the current study, the scope of allylic bromides is increased 
(Scheme 2). Substrates bearing a nitrile group (3g) and alkyl keto group (3h) reacted with excellent  
regioselectivity (γ/α > 49:1). A substrate derived from alkyl aldehyde (3i) was also alkenylated with 
good regioselectivity (γ/α = 24:1).  
Scheme 2. Scope of novel types of MBH alcohols-derived allylic bromides 
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a) Isolated yield of pure product (as a mixture of isomers). b) Determined by 1H NMR (similar values 
were obtained by GC). 
In summary, the first Cu-catalyzed γ-selective allylic alkenylation was developed, employing (E)-
alkenylzinc reagents prepared by Fe-catalyzed reductive coupling of arylacetylenes with alkyl iodides 
and allylic bromides derived from Morita-Baylis-Hillman alcohols. The method uses a simple copper(I) 
catalyst and tolerates a number of important functional groups such as ester, nitrile, keto and nitro. This 
method provides an easy access to highly functionalized 1,4-dienes in high regio- and Z/E-selectivity 
and may be used to prepare libraries of steroid mimics and antitumor drugs, such as aromatase inhibitor 
tamoxifen and related compounds.28 
EXPERIMENTAL SECTION 
General Information 
NMR spectra were recorded on a 400 MHz instrument at ambient temperature in CDCl3 as solvent. 1H 
NMR chemical shifts (δ, ppm) were measured relative to tetramethylsilane (TMS) signal in CDCl3 (0.00 
ppm) unless otherwise stated. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quar-
tet; m, multiplet; br, broad. 13C NMR chemical shifts (δ, ppm) are reported relative to CDCl3 signal 
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(77.16 ppm) unless otherwise stated. The diffraction data were measured at low temperature [100(2) K] 
using Mo Kα radiation on a diffractometer equipped with a kappa geometry goniometer.  
Unless otherwise noted, all chemicals were commercially available and were used as received without 
further purifications. Solvents were purified using a two-column solid-state purification system and 
transferred to glove box without exposure to air by the aid of a Straus flask. Zn powder (<10µ, 98%+) 
was purchased from Aldrich.  Anhydrous dimethylacetamide (DMA) (99.8% purity) was commercially 
purchased and stored under nitrogen. Iron(II) bromide (FeBr2, 98% purity) was purchased from Aldrich 
or Acros. All the chiral starting materials and products were in form of racemic mixtures, for the prod-
ucts containing two stereogenic centers the corresponding diastereomeric ratio was 1:1. Silica gel (40-63 
µm, 230-400 mesh) was used as stationary phase for column chromatography. 
Starting materials preparation 
For additional details about preparation of (E)-alkenylzinc reagents 1a-g see ref. 17,18. All the sub-
strates 3a-i were prepared from corresponding Morita-Baylis-Hillman (MBH) alcohols by treatment 
with HBr/H2SO425 or PBr3.29 For the furylsubstituted substrate 3f PBr3 must be used. In order to obtain 
good yields in allylic substitution reactions, the crude bromides should be purified by column chroma-
tography or (if possible) recrystallized from ether/hexane. 
For the substrates 3a-e, 3g, the starting MBH-alcohols can be prepared by using the procedure from 
ref. 25. MBH-alcohols for preparation of 3f and 3i are synthesized using 1,4-dioxane/water 1:1 mixture 
as solvent, in order to accelerate the reaction.30 In case of the alcohol that corresponds to the bromide 
3h,31 we were unable to separate it from methylvinylketone (MVK) dimer that forms as a side-product. 
However, after the treatment of the product mixture by PBr3, the resulting bromide 3h, can be easily 
isolated from unreacted MVK dimer. All the bromides are obtained as Z-isomers,25,31 with exception of 
3g, which was obtained as a mixture of E- and Z-isomers.32 
General procedures 
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Alkenylzinc reagent solution. Under a dry nitrogen atmosphere a 20 mL screw-cap vial, equipped 
with a magnetic stirring bar, was charged with Zn dust (49 mg, 0.75 mmol), DMA (1 mL) and TMSCl 
(11 mg, 0.1 mmol). The mixture was vigorously shaken for a while and then FeBr2 (11 mg, 0.05 mmol), 
alkyne (0.5 mmol) and alkyl iodide (0.75 mmol) were added. The vial was then sealed and its content 
was allowed to stir overnight (18-20 h) at ambient temperature. 
Allylic alkenylation. A 20 mL screw-cap vial, equipped with a small magnetic stirring bar (to prevent 
splashing the reaction mixture on the walls of the vial), was charged under a dry nitrogen atmosphere 
with allylic bromide (0.25 mmol, 1.0 equiv.), CuCN·2LiCl (0.13 mL of 0.1 M solution in THF, 0.013 
mmol, 5 mol%) and dry degassed DCM (2 mL). The vial was sealed with a rubber septum, taped, and 
cooled to -30°C. Alkenylzinc reagent solution was added using a syringe pump at 1.0 mL/h rate. The 
resulting mixture was allowed to stir for 24 h at -30°C (counting from the beginning of organozinc rea-
gent addition). The mixture was quenched with 1M HCl. n-Dodecane (57 µL, 0.25 mmol) was added, 
and the mixture was extracted into ca. 4 mL of diethyl ether. The ethereal layer was analyzed by GC-MS 
at this point. After that, the content of the vial was poured into water or 1M HCl and extracted with di-
ethyl ether (4 x 10 mL). Combined ether extracts were dried over Na2SO4 and concentrated in vacuo. 
The crude was dried in vacuo, and purified by column chromatography (10-15 g of SiO2, ethyl acetate / 
hexane 1:99 – 10:90). 
If the GC yield is less than 80-85%, to facilitate the chromatographic isolation of the product, the 
crude can be stirred with DABCO (0.25-0.5 mmol) in 2-4 mL of diethyl ether overnight. Then, the ether 
was removed in vacuo and the residue was taken up in a small amount of the eluent for the column 
chromatography purification. 
Ethyl (Z)-5-cyclohexyl-2-methylene-3,4-diphenylpent-4-enoate (4a) 
4a
O
O
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Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3a (67 mg, 0.25 mmol). Yellowish oil, 80.9 mg (87%). Z/E 12:1. 1H NMR (CDCl3, 400 MHz): 
7.29-7.13 (10H, m); 6.28 (1H, s); 5.24 (1H, d, J = 9.9 Hz); 5.08 (1H, s); 4.91 (1H, s); 4.23 (2H, q, J = 
7.0 Hz); 2.1-2.0 (1H, m); 1.64-1.49 (5H, m); 1.30 (3H, t, J = 7.0 Hz); 1.17-1.03 (5H, m). 13C NMR 
(CDCl3, 101 MHz): 167.5; 144.1; 142.2; 139.8; 139.0; 136.2; 129.7; 128.6; 128.4; 128.0; 126.8; 126.6; 
60.9; 55.0; 37.7; 33.6; 33.3; 26.1; 25.7; 25.7; 14.5. Anal. Calcd for C26H30O2: C, 83.38; H, 8.07. Found: 
C, 83.47; H 8.18. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C26H30O2Na  397.2143; Found 397.2144. 
Ethyl (Z)-4-(4-(tert-butyl)phenyl)-5-cyclohexyl-2-methylene-3-phenylpent-4-enoate (4b) 
4b
O
O
t-Bu
 
Prepared from 1-(tert-butyl)-4-ethynylbenzene (79 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 
mmol) and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 90.3 mg (84%). Z/E 12:1. 1H NMR (CDCl3, 
400 MHz): 7.29-7.15 (7H, m); 7.06 (2H, d, J = 7.8 Hz); 6.27 (1H, s); 5.21 (1H, d, J = 10.0 Hz); 5.04 
(1H, s); 4.92 (1H, s); 4.21 (2H, q, J = 7.0 Hz); 2.1-2.0 (1H, m); 1.68-1.50 (5H, m); 1.31-1.27 (12H, m); 
1.16-1.06 (5H, m). 13C NMR (CDCl3, 101 MHz): 167.5; 149.1; 144.4; 140.2; 139.0; 138.5; 136.4; 
129.7; 128.3; 128.1; 126.7; 126.4; 124.8; 60.9; 54.8; 37.6; 34.5; 33.7; 33.4; 31.5; 26.1; 25.7; 25.7; 14.5. 
Anal. Calcd for C30H38O2: C, 83.67; H 8.89. Found: C, 83.67; H 9.13. HRMS (ESI-TOF) m/z: [M+H]+ 
Calcd for C30H39O2 431.2945; Found 431.2946.  
Ethyl (Z)-5-cyclohexyl-4-(4-methoxyphenyl)-2-methylene-3-phenylpent-4-enoate (4c) 
4c
O
O
O
 
Prepared from 1-ethynyl-4-methoxybenzene (66 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 
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mmol) and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 80.2 mg (79%). Z/E 11:1. 1H NMR (CDCl3, 
400 MHz): 7.28-7.16 (5H, m); 7.06 (2H, d, J = 7.9 Hz); 6.76 (2H, d, J = 7.9 Hz); 6.27 (1H, s); 5.21 (1H, 
d, J = 9.9 Hz); 5.05 (1H, s); 4.88 (1H, s); 4.22 (2H, q, J = 7.1 Hz); 3.73 (3H, s); 2.1-2.0 (1H, m); 1.64-
1.43 (5H, m); 1.30 (3H, t, J = 7.1 Hz); 1.19-1.02 (5H, m). 13C NMR (CDCl3, 101 MHz): 167.5; 158.3; 
144.2; 139.9; 138.5; 136.0; 134.5; 129.7; 129.6; 128.4; 126.7; 126.4; 113.4; 60.9; 55.2; 55.1; 37.7; 33.7; 
33.3; 26.1; 25.8; 25.7; 14.5. Anal. Calcd for C27H32O3: C, 80.16; H, 7.97. Found: C, 80.06; H, 8.16. 
Ethyl (Z)-6-ethyl-2-methylene-3-phenyl-4-(p-tolyl)dodec-4-enoate (4d) 
n-C6H13
4d
O
O
 
Prepared from 1-ethynyl-4-methylbenzene (58 mg, 0.5 mmol), 3-iodononane (191 mg, 0.75 mmol) 
and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 78.5 mg (73%). Z/E 57:1. 1H NMR (CDCl3, 400 
MHz): 7.29-7.18 (5H+5H, m); 7.01 (4H+4H, br.s.); 6.30 (1H+1H, s); 5.12 (1H+1H, br.s.); 5.10 
(1H+1H, d, J = 10.7 Hz); 4.93-4.92 (1H+1H, m); 4.29-4.16 (2H+2H, m); 2.26 (3H+3H, s); 
2.01 (1H+1H, br.s.); 1.34-1.05 (15H+15H, m); 0.90-0.84 (6H+3H, m), 0.72 (3H, t, J = 7.4 Hz). 13C 
NMR (CDCl3, 101 MHz): 167.53; 167.48; 144.02; 140.98; 140.91; 139.93; 139.46; 139.41; 135.82; 
135.21; 135.16; 129.85; 129.82; 128.74; 128.72; 128.58; 128.35; 126.76; 126.74; 126.62; 126.59; 60.97; 
60.96; 55.56; 40.00; 39.87; 36.06; 35.82; 32.10; 32.06; 29.74; 29.72; 29.09; 28.85; 27.71; 27.25; 22.91; 
22.82; 21.26; 14.40; 14.29; 14.26; 12.33; 11.85. Anal. Calcd for C30H40O2: C, 83.28; H, 9.32. Found: C, 
83.53; H 9.40. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C30H40O2Na 455.2926; Found 455.2922. 
Ethyl (Z)-4-(4-(tert-butyl)phenyl)-6-methyl-2-methylene-3-phenyloct-4-enoate (4e) 
4e
O
O
t-Bu
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Prepared from 1-(tert-butyl)-4-ethynylbenzene (79 mg, 0.5 mmol), 2-iodobutane (138 mg, 0.75 mmol) 
and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 74.4 mg (74%). Z/E 21:1. 1H NMR (CDCl3, 400 
MHz): 7.29-7.19 (7H + 7H, m); 7.07-7.03 (2H + 2H, m); 6.30-6.28 (1H + 1H, m); 5.18-5.10 (2H+1H, 
m); 5.03 (1H, m); 4.93 (1H, s); 4.91 (1H, s); 4.28-4.18 (2H + 2H, m); 2.21-2.10 (1H + 1H, m); 1.34-
1.26 (14H + 14H, m); 0.98 (3H, d, J = 6.6 Hz); 0.85-0.80 (3H + 3H, m); 0.71 (3H, t, J = 7.4 Hz). 13C 
NMR (CDCl3, 101 MHz): 167.51; 167.49; 149.07; 149.04; 144.44; 144.06; 140.17; 140.02; 139.64; 
139.48; 139.15; 139.13; 136.71; 136.29; 129.77; 129.76; 128.34; 128.19; 128.15; 126.71; 126.70; 
126.57; 126.53; 124.80; 124.77; 60.96; 60.88; 55.07; 54.97; 34.80; 34.51; 34.50; 31.49; 30.45; 30.41; 
21.66; 21.14; 14.45; 14.42; 12.31; 11.96. Anal. Calcd for C28H36O2: C, 83.12; H, 8.97. Found: C, 83.17; 
H 9.06. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C28H36O2Na 427.2613; Found 427.2614. 
Ethyl (Z)-5-(bicyclo[2.2.1]heptan-2-yl)-2-methylene-3-phenyl-4-(p-tolyl)pent-4-enoate (4f) 
4f
O
O
 
Prepared from 1-ethynyl-4-methylbenzene (58 mg, 0.5 mmol), 2-iodobicyclo[2.2.1]heptane (167 mg, 
0.75 mmol) and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 67.9 mg (68%). Z/E 16:1. 1H NMR 
(CDCl3, 400 MHz): 7.29-7.15 (5H + 5H, m); 7.07-7.02 (4H + 4H, m); 6.27 (1H + 1H, br.s.); 5.27-5.23 
(1H + 1H, m); 5.09 (1H, s); 5.06 (1H, s); 4.95-4.93 (1H + 1H, m); 4.25-4.18 (2H + 2H, m); 2.28 (3H + 
3H, s); 2.20-2.08 (2H + 2H, m); 2.02 (1H, br.s.); 1.87 (1H, br.s.); 1.48-1.00 (11H + 11H, m). 13C NMR 
(CDCl3, 101 MHz): 167.49; 167.48; 144.24; 144.21; 140.14; 140.12; 139.02; 138.97; 137.89; 137.84; 
136.03; 135.95; 129.72; 129.67; 128.77; 128.74; 128.64; 128.40; 128.36; 126.75; 126.71; 126.50; 
126.48; 60.87; 54.74; 54.69; 43.55; 43.38; 41.29; 41.24; 40.01; 39.64; 36.76; 36.74; 36.31; 29.58; 
28.94; 28.90; 21.29; 14.45; 14.43. Anal. Calcd for C28H32O2: C, 83.96; H, 8.05. Found: C, 83.91; H, 
8.18. 
Ethyl (Z)-4-(4-chlorophenyl)-5-cyclohexyl-2-methylene-3-phenylpent-4-enoate (4g) 
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4g
O
O
Cl
 
Prepared from 1-chloro-4-ethynylbenzene (68 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) 
and bromide 3a (67 mg, 0.25 mmol). Yellowish oil, 74.5 mg (73%). Z/E 11:1. 1H NMR (CDCl3, 400 
MHz): 7.29-7.24 (2H, m); 7.22-7.18 (5H, m); 7.08-7.04 (2H, m); 6.29 (1H, m); 5.27 (1H, d, J = 9.9 Hz); 
5.06 (1H, m); 4.83 (1H, s); 4.27-4.19 (2H, m); 2.0-1.9 (1H, m); 1.65-1.46 (5H, m); 1.31 (3H, t, J = 7.1 
Hz); 1.19-1.01 (5H, m). 13C NMR (CDCl3, 101 MHz): 167.3; 143.8; 140.6; 139.3; 138.0; 136.5; 132.4; 
129.9; 129.7; 128.5; 128.3; 127.0; 126.7; 61.0; 54.9; 37.8; 33.5; 33.1; 26.0; 25.7; 25.6; 14.5. HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C26H30ClO2 409.1929; Found 409.1924. 
Ethyl (Z)-3-(4-chlorophenyl)-5-cyclohexyl-2-methylene-4-phenylpent-4-enoate (4h) 
4h
O
O
Cl
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3b (76 mg, 0.25 mmol). Yellowish oil, 92.1 mg (90%). Z/E 12:1. 1H NMR (CDCl3, 400 MHz): 
7.25-7.11 (9H, m); 6.30 (1H, s); 5.22 (1H, d, J = 9.9 Hz); 5.09 (1H, s); 4.89 (1H, s); 4.23 (2H, q, J = 7.1 
Hz); 2.1-2.0 (1H, m); 1.65-1.42 (5H, m); 1.30 (3H, t, J = 7.1 Hz); 1.19-0.98 (5H, m). 13C NMR (CDCl3, 
101 MHz): 167.2; 143.7; 141.8; 138.8; 138.4; 136.5; 132.6; 131.0; 128.6; 128.5; 128.1; 126.8; 126.7; 
61.0; 54.4; 37.7; 33.6; 33.2; 26.1; 25.7; 25.7; 14.4. Anal. Calcd for C26H29ClO2: C, 76.36; H, 7.15. 
Found: C, 76.46; H, 7.28. 
Ethyl (Z)-5-cyclohexyl-2-methylene-4-phenyl-3-(4-(trifluoromethyl)phenyl)pent-4-enoate (4i) 
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4i
O
O
F3C
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3c (84 mg, 0.25 mmol). White solid, 92.8 mg (84%). Z/E 12:1. 1H NMR (CDCl3, 400 MHz): 7.54 
(2H, d, J = 7.8 Hz); 7.34 (2H, d, J = 7.9 Hz); 7.26-7.13 (5H, m); 6.33 (1H, s); 5.25 (1H, d, J = 10.0 Hz); 
5.08 (1H, s); 5.00 (1H, s); 4.23 (2H, q, J = 7.0 Hz); 2.1-2.0 (1H, m); 1.66-1.48 (5H, m);  1.31 (3H, t, J = 
7.1 Hz); 1.20-1.00 (5H, m). 13C NMR (CDCl3, 101 MHz): 167.1; 144.2; 143.3; 141.7; 138.4; 137.1; 
130.0; 129.2 (q, JC-F = 32.4 Hz); 128.5; 128.2; 126.9; 126.9; 125.4 (q, JC-F = 3.8 Hz); 124.4 (q, JC-F = 
272.0 Hz); 61.1; 54.7; 37.7; 33.5; 33.2; 26.1; 25.7; 25.6; 14.4. Anal. Calcd for C27H29F3O2: C, 73.28; H, 
6.61. Found: C, 73.18; H, 6.73. 
 
Ethyl (Z)-3-(4-cyanophenyl)-5-cyclohexyl-2-methylene-4-phenylpent-4-enoate (4j) 
4j
O
O
NC
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3d (74 mg, 0.25 mmol). Yellowish oil, 91.7 mg (92%). Z/E 13:1. 1H NMR (CDCl3, 400 MHz): 
7.58 (2H, d, J = 8.2 Hz); 7.34 (2H, d, J = 8.2 Hz); 7.27-7.11 (5H, m); 6.35 (1H, s); 5.22 (1H, d, J = 10.0 
Hz); 5.10 (1H, s); 5.00 (1H, s); 4.23 (2H, qd, J = 7.1 Hz, 2.2 Hz); 2.1-2.0 (1H, m); 1.65-1.48 (5H, m); 
1.30 (3H, t, J = 7.1 Hz); 1.18-1.01 (5H, m). 13C NMR (CDCl3, 101 MHz): 166.8; 145.8; 142.7; 141.3; 
138.0; 137.4; 132.3; 130.4; 128.4; 128.2; 127.0; 126.9; 118.9; 110.8; 61.2; 54.9; 37.7; 33.4; 33.1; 26.0; 
25.6; 25.6; 14.4. Anal. Calcd for C27H29NO2: C, 81.17; H, 7.32; N, 3.51. Found: C, 81.16; H, 7.39; 
N, 3.45. 
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Ethyl (Z)-5-cyclohexyl-2-methylene-3-(2-nitrophenyl)-4-phenylpent-4-enoate (4k) 
4k
O
O
NO2
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3e (79 mg, 0.25 mmol). Yellowish solid, 51.9 mg (49%). Z/E 16:1. 1H NMR (CDCl3, 400 MHz): 
7.85 (1H, d, J = 8.0 Hz); 7.58-7.53 (2H, m); 7.39-7.35 (1H, m); 7.28-7.18 (5H, m); 6.42 (1H, s); 5.71 
(1H, s); 5.29 (1H, s); 5.13 (1H, d, J = 10.0 Hz); 4.19 (2H, q, J = 7.0 Hz); 2.1-2.0 (1H, m); 1.62-1.49 
(5H, m); 1.25 (3H, t, J = 7.1 Hz); 1.15-0.97 (5H, m). 13C NMR (CDCl3, 101 MHz): 166.5; 150.0; 141.7; 
141.0; 138.2; 137.6; 134.8; 132.5; 131.2; 128.7; 128.2; 127.8; 127.3; 127.0; 125.1; 61.2; 49.6; 37.8; 
33.4; 33.2; 26.0; 25.6; 14.3. HRMS (ESI-TOF) m/z: [M+Na]+ Calcd for C26H29NNaO4 442.1994; Found 
442.1994. 
Ethyl (Z)-5-cyclohexyl-3-(furan-2-yl)-2-methylene-4-phenylpent-4-enoate (4l) 
4l
O
O
O
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3f (65 mg, 0.25 mmol). Yellowish oil, 68.6 mg (75%). Z/E 11:1. 1H NMR (CDCl3, 400 MHz): 
7.35-7.21 (6H, m); 6.33 (1H, br.s.); 6.28 (1H, br.s.); 6.13 (1H, m); 5.27 (1H, br.s.); 5.25 (1H, d, J = 10.3 
Hz); 4.95 (1H, s); 4.22 (2H, q, J = 7.1 Hz); 2.1-2.0 (1H, m); 1.64-1.48 (5H, m); 1.28 (3H, t, J = 7.1 Hz); 
1.11-0.99 (5H, m). 13C NMR (CDCl3, 101 MHz): 166.8; 154.3; 142.1; 141.5; 141.2; 136.9; 136.4; 
128.7; 128.0; 126.8; 126.4; 110.2; 108.8; 60.9; 48.6; 37.6; 33.4; 33.2; 26.1; 25.7; 25.6; 14.4. HRMS 
(ESI-TOF) m/z: [M+H]+ Calcd for C24H29O3 365.2117; Found 365.2119.  
(Z)-5-Cyclohexyl-2-methylene-3,4-diphenylpent-4-enenitrile (4m) 
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4m
CN
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3g (56 mg, 0.25 mmol). Yellowish oil, 52.8 mg (64%). Z/E 24:1. 1H NMR (CDCl3, 400 MHz): 
7.34-7.20 (8H, m); 7.08-7.06 (2H, m); 6.00 (1H, d, J = 1.1 Hz); 5.41 (1H, d, J = 1.5 Hz); 5.39 (1H, d, J 
= 10.1 Hz); 4.48 (1H, s); 2.1-2.0 (1H, m); 1.69-1.54 (5H, m); 1.21-1.11 (5H, m). 13C NMR (CDCl3, 101 
MHz): 140.9; 138.8; 137.5; 136.9; 132.3; 129.4; 128.8; 128.5; 128.3; 127.7; 127.0; 126.1; 118.9; 57.7; 
38.0; 33.3; 33.1; 26.1; 25.7; 25.6. Anal. Calcd for C24H25N: C, 88.03; H, 7.70; N, 4.28. Found: C, 88.09; 
H, 7.49; N, 4.29. 
(Z)-6-Cyclohexyl-3-methylene-4,5-diphenylhex-5-en-2-one (4n) 
4n
O
 
Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3h (60 mg, 0.25 mmol). Yellowish oil, 74.8 mg (87%). Z/E 13:1. 1H NMR (CDCl3, 400 MHz): 
7.28-7.15 (10H, m); 6.14 (1H, s); 5.35 (1H, d, J = 1.3 Hz); 5.12 (1H, d, J = 9.9 Hz); 5.04 (1H, s); 2.34 
(3H, s); 2.05-1.95 (1H, m); 1.62-1.50 (5H, m); 1.11-0.98 (5H, m). 13C NMR (CDCl3, 101 MHz): 199.3; 
151.9; 142.1; 140.2; 139.2; 136.3; 129.6; 128.5; 128.4; 128.0; 126.7; 126.6; 53.5; 37.6; 33.6; 33.4; 26.8; 
26.1; 25.7; 25.6. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C25H29O 345.2213; Found 345.2204.  
Ethyl (Z)-5-cyclohexyl-3-ethyl-2-methylene-4-phenylpent-4-enoate (4o) 
4o
O
O
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Prepared from phenylacetylene (51 mg, 0.5 mmol), iodocyclohexane (158 mg, 0.75 mmol) and bro-
mide 3i (55 mg, 0.25 mmol). Yellowish oil, 78.5 mg (96%). Z/E > 10:1. γ/α 24:1. 1H NMR (CDCl3, 400 
MHz): 7.30-7.25 (2H, m); 7.23-7.19 (1H, m); 7.09-7.07 (2H, m); 6.20 (1H, d, J = 0.7 Hz); 5.34 (1H, m); 
5.27 (1H, d, J = 9.9 Hz); 4.19 (2H, q, J = 7.1 Hz); 3.41 (1H, t, J = 7.3 Hz); 1.9-1.8 (1H, m); 1.62-1.47 
(7H, m); 1.29 (3H, t, J = 7.1 Hz); 1.11-1.02 (5H, m); 0.90 (3H, t, J = 7.4 Hz). 13C NMR (CDCl3, 101 
MHz): 167.9; 142.7; 141.1; 139.3; 135.3; 129.2; 127.8; 126.4; 123.9; 60.7; 50.1; 37.7; 33.5; 33.5; 26.1; 
25.7; 25.1; 14.4; 12.5. HRMS (ESI-TOF) m/z: [M+H]+ Calcd for C22H31O2 327.2319; Found 327.2313. 
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